Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay181 in Advanced Solid Tumors
NCT05749432Phase 1Recruiting
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Mar 2023
- Primary completion
- Jan 2026
- Modality
- Bivalent/Multivalent Binders, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Hemay181 in solid tumor, sponsored by Hemay Pharmaceutical Technology. Primary endpoints: Number of participants with adverse events at 3 weeks, Incidence of dose-limiting toxicity (DLT) in each dose group at 3 weeks and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
Hemay181
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05749432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749432.